Saturday , May 4 2024
Home / Mike Norman Economics / Randomized but unblinded experiment on vitamin D as a coronavirus treatment. Let’s talk about what comes next. (Hint: it involves multilevel models.) — Andrew Gelman

Randomized but unblinded experiment on vitamin D as a coronavirus treatment. Let’s talk about what comes next. (Hint: it involves multilevel models.) — Andrew Gelman

Summary:
Of interest statistically.Statistical Modeling, Causal Inference, and Social ScienceRandomized but unblinded experiment on vitamin D as a coronavirus treatment. Let’s talk about what comes next. (Hint: it involves multilevel models.) Andrew Gelman | Professor of Statistics and Political Science and Director of the Applied Statistics Center, Columbia UniversityAnother studyPLOSVitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection Zhila Maghbooli,Mohammad Ali Sahraian ,Mehdi Ebrahimi,Marzieh Pazoki,Samira Kafan,Hedieh Moradi Tabriz,Azar Hadadi,Mahnaz Montazeri,Mehrad Nasiri,Arash Shirvani,Michael F. Holick

Topics:
Mike Norman considers the following as important:

This could be interesting, too:

Nick Falvo writes Canada’s 2024 federal budget: What’s in it for rental housing and homelessness?

Robert Vienneau writes Precursors Of The Modern Revival Of Classical Political Economy

NewDealdemocrat writes The snooze-a-than in jobless claims continues; what I am looking for in tomorrow’s jobs report

Bill Haskell writes Monthly payments could get thousands of homeless people off the streets


Of interest statistically.

Statistical Modeling, Causal Inference, and Social Science
Randomized but unblinded experiment on vitamin D as a coronavirus treatment. Let’s talk about what comes next. (Hint: it involves multilevel models.)
Andrew Gelman | Professor of Statistics and Political Science and Director of the Applied Statistics Center, Columbia University

Another study

PLOS
Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection
Zhila Maghbooli,Mohammad Ali Sahraian ,Mehdi Ebrahimi,Marzieh Pazoki,Samira Kafan,Hedieh Moradi Tabriz,Azar Hadadi,Mahnaz Montazeri,Mehrad Nasiri,Arash Shirvani,Michael F. Holick

Mike Norman
Mike Norman is an economist and veteran trader whose career has spanned over 30 years on Wall Street. He is a former member and trader on the CME, NYMEX, COMEX and NYFE and he managed money for one of the largest hedge funds and ran a prop trading desk for Credit Suisse.

Leave a Reply

Your email address will not be published. Required fields are marked *